Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.49 |
| ▸ | GABRD | O14764 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846673 | 0.91 | MAPT (0.68) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL9150772 | 0.87 | MAPT (0.68) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL2268884 | 0.86 | MAPT (0.75) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL26120557 | 0.85 | TDP1 (0.53) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL27642918 | 0.80 | TTR (0.66) | MAPTALDH1A1SMN1; SMN2CA12CA1 | |
| SCHEMBL8954247 | 0.80 | TTR (0.66) | MAPTALDH1A1SMN1; SMN2CA12CA1 | |
| SCHEMBL2525113 | 0.79 | MAPT (0.55) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL9148081 | 0.79 | MAPT (0.55) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL11625037 | 0.78 | LMNA (0.62) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL8954231 | 0.78 | ELANE (0.55) | MAPTALDH1A1NPC1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200551-A1 | Flourene Derivative | ASTELLAS PHARMA INC. (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | ASTELLAS PHARMA INC. (JP) | 2008-07-17 | — | — | US | disclosed |
| US-20080161419-A1 | Prophylactic Antimigraine Agents | ASTELLAS PHARMA INC. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852129-A1 | REMEDY FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1728784-A1 | FLUORENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-1716867-A1 | PREVENTIVES FOR MIGRAINE | Astellas Pharma Inc. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161419-A1 | Prophylactic Antimigraine Agents | HTR2B, HTR7, HTR1A | MAPT 3582/4885LMNA 1512/4885ALDH1A1 2787/4885 |
| US-20080200551-A1 | Flourene Derivative | HTR2B, HTR7, HTR2C | MAPT 3927/4885LMNA 2620/4885ALDH1A1 3293/4885 |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | HTR7, HTR5A, HTR3B | MAPT 4073/4885LMNA 4613/4885ALDH1A1 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.